INTIStock

Inhibitor Therapeutics, Inc.

About Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc. (INTI) is a publicly listed company on US equity markets.

INHIBITOR THERAPTICS INC

The company reports trailing twelve-month revenue of $0 and net loss of $686,425.

Key metrics include a return on equity of 34.7%, a debt-to-equity ratio of -1.72.

Use FINOTAUR to track INTI's price action, review fundamentals, and stay current with company news — all in one research dashboard.

Fundamentals

Revenue (TTM)$0
Net Income (TTM)$-686,425
EPS (TTM)
P/E Ratio
Return on Equity34.70%
Debt-to-Equity-1.72
Dividend per Share

Want real-time analysis on INTI?

Track it free in your trading journal. Log trades, tag setups, and review your edge.

Get started